Objective    To investigate the correlation of XRCC1 Arg399Gln polymorphisms with chemoradiotherapy sensitivity in Chinese patients with locally advanced esophageal cancer.  Methods    A total of 122 cases with pathologically confirmed advanced esophageal cancer who were admitted in our hospital from March 2009 to March 2013 were recruited in this study. Intensity-modulated radiation therapy (IMRT) plan was designed for the primary tumors and lymph drainage area

and the primary lesion was given 40 Gy/20f and prior TP scheme chemotherapy. Direct sequencing is used to analyze the XRCC1 single nucleotide polymorphisms in the 122 cases. Kaplan-Meier method was used to analyze the correlation of XRCC1 gene classification with the total survival time.   Results    XRCC1 gene polymorphisms showed the following expression patterns Arg399Gln GG

GA and AA

and the distribution frequency were 54 cases (44.3%)

49 cases (40.2%)

and 19 cases (15.5%) in the subjects. The median overall survival time was 41 months (95%CI: 37.2~44.8). The median overall survival time was 52.9

35.9 and 28.0 months respectively for the carriers of GG

GA and AA genotypes (Log-Rank

P0.01). The carriers of GA and AA genotypes had a significantly increased risk for death when compared with the GG genotype patients (GA vs GG

HR=3164

95%CI: 1.914～5.230; AA vs GG

HR=6.868

95%CI: 3.549～13.289).  Conclusion     XRCC1 Arg399Gln single nucleotide polymorphisms are associated with esophageal radiation and chemotherapy sensitivity. The GG genotype carriers have better prognosis after chemoradiotherapy.